Press Releases

Purolite Grows Bioprocessing Production Capacity with New U.S. Manufacturing Facility

Landenberg site strengthens supply to support lifesaving therapeutics for global customers

Samsung Biologics and Pfizer announce strategic collaboration for long-term manufacturing of biosimilars portfolio

Xlpe Cable Market is estimated to be US$ 3.09 billion by 2030 with a CAGR of 6.2% during the forecast period

The Xlpe cables market accounted for US$ 1.70 billion in 2020 and is estimated to be US$ 3.09 billion by 2030 and is anticipated to register a CAGR of 6.2%. Cross linked polyethylene insulated aluminium conductor armoured cable is referred to as XLPE cable. It is a fundamental necessity of power networks used in the transmission and distribution of electricity to consumers. These cables are categorised into four voltage groups based on their application: low voltage, medium voltage, high voltage, and extra-high voltage, and are used in transmission lines ranging from 600V to 1000 kV.XLPE cables are utilised for extended distances where dielectric losses are significant. These cables have a higher insulation value, are lighter, and have a higher current capacity.

Samsung Biologics accelerates timeline of new fifth plant to be operational by April 2025

Quanticate announces strategic partnership with KPS Life

Cmed and Larix fully integrated into Aixial Group, the CRO solution of ALTEN Group

Kristin Judge Joins Emmes as Chief Growth Officer

Notes to Editor: About Emmes Founded more than 45 years ago, Emmes is a global, full-service Clinical Research Organization dedicated to excellence in supporting the advancement of public health and biopharmaceutical innovation. The company’s clients include numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world. To learn more about how our research is making a positive impact on human health, go to the Emmes website at www.emmes.com. For media enquiries, please contact: Alex Heeley or Nidhi Narain De Facto Communications T: +44 (0) 203 735 8165 / +44 (0) 7769015043 E: n.narain@defacto.co.uk / a.heeley@defacto.co.uk

CTMC MARKS ONE YEAR OF ACCELERATING LIFE-SAVING CELL THERAPIES TO PATIENTS

CTMC, a joint venture between MD Anderson Cancer Center and Resilience, celebrates one year since its founding to accelerate life-saving cell therapies reaching patients.

Amerigo Scientific Distributes Highly Purified Human tRNA Reagents to Accelerate HIV Research

CD Formulation Exhibits Proficiency in Contact Angle Determination of Pharmaceutical Excipients

Biopharma PEG Supplies PEG Products For 3D Bioprinting

Biopharma PEG Scientific Inc. Address: 108 Water Street, Room 4D, Watertown, MA 02472, USA TEL: 1-857-366-6766 Fax: 617-206-9595 Email: sales@biochempeg.com Website:https://www.biochempeg.com/

Huateng Pharma Announced To Attend CPhI China In June 2023

Hunan Huateng Pharmaceutical Co. Ltd. Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, China Manufacturing Base: Tongguan Kiln, Wangcheng district, Changsha, Hunan, China Email: sales@huatengusa.com Website: https://us.huatengsci.com Zip code: 410205 Telephone: +86 731 89916275 Fax: +86 0731-82251112-818

Synexa Life Sciences Joins CEPI in Advancing Global Epidemic Preparedness and Response

Synexa Life Sciences, a specialist biomarker and bioanalysis service provider, has announced its membership in the Coalition for Epidemic Preparedness Innovations (CEPI) esteemed Central Lab Network, to improve global epidemic preparedness. CEPI is an innovative partnership between public, private, philanthropic, and civil organizations to develop vaccines against future epidemics. This strategic partnership represents a significant milestone in Synexa's commitment to global health security and its dedication to fostering collaboration and innovation in epidemic preparedness and response.

Creative Enzymes Revolutionizes the Probiotics Industry with Bacillus Coagulans Freeze Dried Powder

Creative Enzymes Elevates Your Industrial Processes with Enzymes for Industrial Use

Oncodesign Services and Veritas In Silico enter into business cooperation on developing mRNA-targeted small molecule drugs

Oncodesign Services has announced it has entered into a Memorandum of Understanding with Veritas In Silico to respond to the needs of pharmaceutical companies seeking to develop innovative small molecule drugs targeting mRNA.

Mural Health and China-based Clinflash Partner to Expand Global Patient Payment Solutions

Next-Generation eCOA/ePRO Provider uMotif Welcomes SAFIRA Clinical Research Co-founder and Clinical Trial Technology Innovator Willie Muehlhausen as Scientific Advisor

Muehlhausen is a trusted name in independent, scientific evaluation of patient-facing technologies; also known for his ability to envision and develop groundbreaking solutions for eCOA/ePRO and wearables.

New Partnership Established: Alfa Chemistry Adds 200,000+ Chemicals to Spaya Database

Lonza Launches TheraPEAK® T-VIVO® Cell Culture Medium to Accelerate Cell Therapy Development

Lonza has launched the TheraPEAK® T-VIVO® Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing.